Nonalcoholic fatty liver disease

Textbook of Clinical Gastroenterology and Hepatology: Second Edition

Volumn , Issue , 2012, Pages 658-674

  Mccullough, Arthur J ^a   Dasarathy, Srinivasan ^a  

^a CASE WESTERN RESERVE UNIVERSITY   (United States)

Author keywords

Bariatric surgery; Comorbidities; Insulin resistance; Liver biopsy; Metabolic syndrome; Natural history; Non alcoholic fatty liver disease; Non alcoholic steatohepatitis; Prevalence; Vitamin E

Indexed keywords

EID: 84891400789     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9781118321386.ch89     Document Type: Chapter

References (57)

1. Tetri BA, Clark JM, Bass NM, et al. For the NASH Clinical Research Network. Clinical, laboratory and histological association in adults with nonalcoholic fatty liver disease. Hepatology. 2010;52:913-924.
2. Targher G, Day CP, Bonora E. Risk of cardiovascular disease in patients with nonalcoholic fatty liver disease. N Engl J Med. 2010;363:L1341-1350.
3. Baumeister SE, Volzke H, Marshall P. Impact of fatty liver disease on health care utilization and costs in a general population: A five year observation. Gastroenterology. 2008;134:85-94.
4. Charlton M. Nonalcoholic fatty liver disease: A review of current understanding and future impact. Clin Gastroenterol Hepatol. 2004;2:1048-1058.
5. Hall PM, Kirsch R. (2005) Pathology of hepatic steatosis, NASH and related complications, in Fatty Liver Disease: NASH and Related Disorders. (eds G.C. Farrell, J. George, P. Hall and A.J. McCullough. Blackwell Publishing, Oxford, pp. 13-22.
6. Matteoni CA, Younossi ZM, Gramlich T, et al. Nonalcoholic fatty liver: A spectrum of clinical and pathologic severity. Gastroenterology. 1999;116:1413-1419.
7. Kleiner DE, Brunt EM, Vannatta M, et al. and the nonalcoholic steatohepatitis clinical research network. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology. 2005;41:1313-1321.
8. Adams LA, Lymp JF, St. Sauver J. The natural history of nonalcoholic fatty liver disease: A population based cohort study. Gastroenterology. 2005;129:113-121.
9. Bellentani S, Bedogni G, Miglioli L. The epidemiology of fatty liver. Eur J Gastroenterol Hepatol. 2004;16:1087-1093.
10. Everhart JE, Bambha KM. Fatty liver: Think globally. Hepatology. 2010;51:1491-1493.
11. Dasarathy S, Dasarathy J, Khiyami A, et al. Validity of real time ultrasound in the diagnosis of hepatic steatosis: A prospective study. J Hepatol. 2009;51:1061-1067.
12. Browning JD, Szezepaniak LS, Dobbins R, et al. Prevalence of hepatic steatosis in an urban population in the United States: Impact of ethnicity. Hepatology. 2004;40:1387-1395.
13. Almeda-Valdes P, Cuebas-Ramus D, Aquilar-Salinas CA. Metabolic syndrome and nonalcoholic fatty liver disease. Ann Hepatol. 2009;8:18-24.
14. Alberti KGMN, Zimmet P, Shaw J. For the Epidemiology Task Force Consensus Group. The metabolic syndrome-A new world definition. Lancet. 2005;366:1059-1063.
15. Lorenzo C, Stern MP, Okoloise M, et al. The metabolic syndrome as a predictor of Type 2 diabetes. Diabetes Care. 2003;26:3153-3159.
16. Kahabuchi M, Kojina T, Takeda N, et al. The metabolic syndrome as a predictor of nonalcoholic fatty liver disease. Ann Intern Med. 2005;142:722-728.
17. Marchesini G, Ragianesi B, Forlani G, et al. Nonalcoholic fatty liver, steatohepatitis and the metabolic syndrome. Hepatology. 2003;37:917-923.
18. Younossi ZM, Gramlich T, Matteoni CA, et al. Nonalcoholic fatty liver disease in patient with Type 2 diabetes. Clin Gastroenterol Hepatol. 2004;2:262-265.
19. Pagadala M, Zein CO, McCullough AJ. Predictors of steatohepatitis and advanced fibrosis in nonalcoholic liver disease. Clin Liv Dis. 2009;13:591-606.
20. Feldstein AE, Wieckowska A, Lopez AR, et al. Cyto-keratin-18 fragment levels as a non-invasive marker of nonalcoholic steatohepatitis: A multicenter validation study. Hepatology. 2009;50: 1072-1078.
21. Guha IN, Parkes J, Roderick P. Non-invasive markers of fibrosis in nonalcoholic fatty liver disease: Validating the European liver fibrosis panel and exploring simple markers. Hepatology. 2008; 47:455-460.
22. Angulo P, Hui JM, Marchesini G, et al. The NAFLD fibrosis score: A non-invasive system that identifies liver fibrosis in patients with NAFLD. Hepatology. 2007;45:846-854.
23. Younossi ZM, Baranova A, Ziegler H. A genomic and proteomic study of the spectrum of nonalcoholic liver diseases. Hepatology. 2005;42:655-674.
24. Kalhan SC, Guo L, Edmison J, et al. Plasma metabolomic profile in nonalcoholic fatty liver disease. Metabolism. 2011;60:404-413.
25. Cheung O, Sanyal AJ. Recent advances in nonalcoholic fatty liver disease. Curr Opin Gastroenterol. 2010;26:202-208.
26. Feldstein AE. Novel insights into the pathophysiology of nonalcoholic fatty liver disease. Semin Liver Dis. 2010;30:391-401.
27. Trauner M, Arrese M, Wagner M. Fatty liver and lipotoxicity. Biochim Biophys Acta. 2010;1801:299-310.
28. Musso G, Gambino R, Cassader M. Gut microbiota as a regulator of energy homeostasis and ectopic fat deposition: Mechanisms and implications for metabolic disorders. Curr Opin Lipidol. 2010;21:76-83.
29. Chalasani N, Wilson L, Kleiner DE, et al. For the NASH Clinical Research Network. Relationship of steatosis grade and zonal location to histological features of steatohepatitis in adult patients with nonalcoholic fatty liver disease. J Hepatol. 2008;48:829-834.
30. Brunt EM, Kleiner DW, Wilson LA, et al. For the Clinical Research Network. Portal inflammation in nonalcoholic fatty liver disease (NAFLD): A histologic marker of advanced NAFLD clinicopathologic correlations from the Nonalcoholic Steatohepatitis Clinical Research Network. Hepatology. 49:809-820.
31. Loomba R, Sirlin CB, Schwimmer JB, et al. Advances in pediatric nonalcoholic fatty liver disease. Hepatology. 2009;50:1282-1293.
32. Newton JL, Jones DEJ, Henderson E, et al. Fatigue in nonalcoholic fatty liver disease (NAFLD) is significant and associates with inactivity and excessive daytime sleepiness but not with liver disease severity or insulin resistance. Gut. 2008;57: 807-813.
33. Ruhl CE, Everhart JE. Joint effects of body weight and alcohol on elevated serum alanine aminotransferase in the United States population. Clin Gastroenterol Hepatol. 2005;3:1260-1268.
34. McCullough AJ. The clinical features, diagnosis and natural history of nonalcoholic fatty liver disease. Clin Liver Dis. 2004;8:521-533.
35. Dunn W, Angulo P, Sanderson S, et al. Utility of a new model to diagnose an alcohol basis for steatohepatitis. Gastroenterology. 2006;131:1057-1063.
36. Vuppalanchi R, Chalasani N. Nonalcoholic steatohepatitis: Selected practical issues in their evaluation and management. Hepatology. 2009;49:306-317.
37. Saadeh S, Younossi ZM, Remer EM, et al. The utility of radiological imaging in nonalcoholic fatty liver disease. Gastroenterology. 2002;123:745-750.
38. Mofrad P, Contos MJ, Hague M. Clinical and histological spectrum of nonalcoholic fatty liver disease associated with normal ALT values. Hepatology. 2003;37:1286-1292.
39. Lam B, Younossi AM. Treatment options for nonalcoholic fatty liver disease. Ther Adv Gastroenterol. 2010;3:121-137.
40. Federico A, Niosi M, DelVecchio Blanco C, et al. Emerging drugs for nonalcoholic fatty liver disease. Expert Opin Emerging Drugs. 2008;13:145-158.
41. Youssef WI, McCullough AJ. Diabetes mellitus, obesity and hepatic steatosis. Semin Gastrointestinal Dis. 2002;13:1730.
42. Promrat K, Fleiner DE, Niemeier HM, et al. Randomized controlled trial testing the effects of weight loss on nonalcoholic steatohepatitis. Hepatology. 2010;51:121-129.
43. Bellentani S, Grave RD, Suppini A, et al, and the Fatty Liver Italian Network. Behavior therapy for nonalcoholic fatty liver: The need for a multidisciplinary approach. Hepatology. 2008;47: 746-754.
44. Harrison SA, Fecht W, Brunt EM, et al. Orlistar for overweight subjects with nonalcoholic steatohepatitis: A randomized, prospective trial. Hepatology. 2009;49:80-86.
45. Mummadi R, Kasturi KS, Chennareddy S, et al. Effect of bariatric surgery on nonalcoholic fatty liver disease: Systematic review and meta analysis. Clin Gastroenterol Hepatol. 2008;6:1396-1402.
46. Chavez-Tapia NC, Tellez-Avilla FI, Barrientes-Guitierrez T, et al. Bariatric surgery for nonalcoholic steatohepatitis in obese patients (Review). Cochrane Database Sys Rev 2010;20:CD 007340. www.thecochranelibrary.com
47. Schroeder H. Protective mechanisms of the Mediterranean diet in obesity and type 2 diabetes. J Nutr Biochem. 2007;18:149-160.
48. Esposito K, Marfella R, Ciotola M. Effect of a Mediterranean diet on endothelial function and markers of vascular inflammation in the metabolic syndrome. JAMA. 2004;292:1440-1446.
49. Georgescu EF, Ioneschu R, Niculessu M, et al. Angiotensivereceptor blockers as therapy for mild-to-moderate hypertensionassociated nonalcoholic steatohepatitis. World J Gastroenterol. 2009;28:942-954.
50. Angelico F, Burattin M, Alessandri C, et al. Drugs improving insulin resistance for nonalcoholic fatty liver disease and/or nonalcoholic steatohepatitis. Cochrane Database Sys Rev 2007;CD005166.
51. Sanyal AJ, Chalasani N, Kowdley KV, et al. For the NASH CRN. Pioglitazone, vitamin E or placebo for nonalcoholic steatohepatitis. N Engl J Med. 2010;362:1675-1885.
52. Zarich SW. Does the choice of antidiabetic therapy influence macrovascular outcome? Curr Diab Rep. 2010;10:24-31.
53. Ascha MS, Hanouneh IA, Lopez R, et al. The incidence and risk factors of hepatocellular carcinoma in patients with nonalcoholic steatohepatitis. Hepatology. 2010;51:1972-1978.
54. Eckstedt M, Franzen LE, Mathiesen UL, et al. Longterm followup of patients with NAFLD and elevated enzymes. Hepatology. 2006;44:865-873.
55. Feldstein AE, Charatcharoenwitthaya P, Treeprasertsuk S, et al. Natural history of nonalcoholic fatty liver disease in children: A follow-up study up to 20 years. Gut. 2009;58:1538-1544.
56. Pagadala M, Dasarathy S, Eghtesad B, et al. Post transplant metabolic syndrome: An epidemic waiting to happen. Liver Transpl. 2009;15:1662-1670.
57. Franz MJ, Bantle JP, Beebe JD. American Diabetes Association nutrition principles and recommendation in diabetes. Diabetes Care. 2004;27:526-546.